ARMGO is a venture-backed biotech company developing Rycals®, novel small molecule drugs that target the ryanodine receptor calcium ion channels (RyR).

We will soon be sharing a new look for our company.

In the meantime, to learn more about our world-class science and RyR-targeting drug development please contact us at info@armgo.com.